More importantly, studies have shown that not only does sGC inhibitor treatment suppress tumor growth and proliferation in TMPRSS2-ERG-positive PCa xerographs, but that it can also act strategically with an AR antagonist such as enzalutamide [90]. Here, TMPRSS2 is linked to neoplasm.